Trials / Recruiting
RecruitingNCT06487078
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
LOREA : ANALYSIS OF THE EFFECTIVENESS AND SAFETY OF LORLATINIB IN UNTREATED ALK-POSITIVE NSCLC PATIENTS IN A FRENCH NON INTERVENTIONAL STUDY
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World context
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lorlatinib | ALK-positive NSCL treatment |
Timeline
- Start date
- 2025-01-20
- Primary completion
- 2028-11-30
- Completion
- 2028-11-30
- First posted
- 2024-07-05
- Last updated
- 2026-03-27
Locations
4 sites across 1 country: France
Source: ClinicalTrials.gov record NCT06487078. Inclusion in this directory is not an endorsement.